SG11201900132QA - Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy - Google Patents

Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Info

Publication number
SG11201900132QA
SG11201900132QA SG11201900132QA SG11201900132QA SG11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA SG 11201900132Q A SG11201900132Q A SG 11201900132QA
Authority
SG
Singapore
Prior art keywords
international
neoepitopes
rule
disease
pct
Prior art date
Application number
SG11201900132QA
Inventor
Arbel D Tadmor
Ugur Sahin
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of SG11201900132QA publication Critical patent/SG11201900132QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0111010101111101111101 0 0111111 HE 100 11111 01H 1111E11E1111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/015433 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: GOOF 19/00 (2018.01) A61K 39/00 (2006.01) Published: C12Q 1/68 (2018.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/EP2017/068226 amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 19 July 2017 (19.07.2017) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2016/067348 20 July 2016 (20.07.2016) EP (71) Applicant: BIONTECH RNA PHARMACEUTICALS GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). (72) Inventors: TADMOR, Arbel D.; Am Anger 10, 55294 Bo- _ denheim (DE). SAHIN, Ugur; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). = = (74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwalte PartG _ mbB, Hansastrasse 32, 80686 Mfinchen (DE). = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, _= = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States (unless otherwise indicated, for every — (84) _ _ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = under Rule 4.17: en Declarations ..! — as to the applicant's entitlement to claim the priority of the M earlier application (Rule 4.17(iii)) M 71' ir) Il © (54) Title: SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH ENHANCED EFFICACY --.... ,-1 (57) : The present invention relates to methods for determining whether neoepitopes that are only expressed in or on diseased 0 cells arc suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance, and use of \" the neoepitopes in providing an immune response against diseased cells expressing the neoepitopes.
SG11201900132QA 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy SG11201900132QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016067348 2016-07-20
PCT/EP2017/068226 WO2018015433A2 (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Publications (1)

Publication Number Publication Date
SG11201900132QA true SG11201900132QA (en) 2019-02-27

Family

ID=59399416

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201900132QA SG11201900132QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
SG10201912678QA SG10201912678QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912678QA SG10201912678QA (en) 2016-07-20 2017-07-19 Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Country Status (22)

Country Link
US (1) US20190189241A1 (en)
EP (2) EP3967324A1 (en)
JP (2) JP7171543B2 (en)
KR (2) KR20230019223A (en)
CN (2) CN117757931A (en)
AU (1) AU2017299162A1 (en)
BR (1) BR112018077122A8 (en)
CA (1) CA3031003A1 (en)
CY (1) CY1124551T1 (en)
DK (1) DK3488443T3 (en)
ES (1) ES2890424T3 (en)
HR (1) HRP20211443T1 (en)
HU (1) HUE056660T2 (en)
IL (1) IL264203B1 (en)
LT (1) LT3488443T (en)
MX (1) MX2019000733A (en)
PL (1) PL3488443T3 (en)
PT (1) PT3488443T (en)
RS (1) RS62390B1 (en)
SG (2) SG11201900132QA (en)
SI (1) SI3488443T1 (en)
WO (1) WO2018015433A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009070A (en) 2017-02-01 2019-10-30 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides.
AU2018348249A1 (en) * 2017-10-12 2020-04-16 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
CN109294983A (en) * 2018-09-30 2019-02-01 北京鼎成肽源生物技术有限公司 A kind of LFF2 cell
CN111402954B (en) * 2019-01-02 2023-07-21 中国人民解放军军事科学院军事医学研究院 Method for identifying and predicting human genes related to space radiation injury protection drug targets

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
ATE449193T1 (en) 2006-04-12 2009-12-15 Medical Res Council METHOD FOR DETERMINING THE COPY NUMBER
EP2198292A4 (en) 2007-08-21 2010-09-08 Univ Washington Improved alzheimer's diagnosis
AU2008295992B2 (en) 2007-09-07 2014-04-17 Fluidigm Corporation Copy number variation determination, methods and systems
EP3699266A1 (en) * 2010-05-14 2020-08-26 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
DK2714071T3 (en) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh INDIVIDUALIZED VACCINES AGAINST CANCER
KR102134932B1 (en) * 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 Cyclin a1 -targeted t-cell immunotherapy for cancer
US9569586B2 (en) * 2012-02-13 2017-02-14 Albert Rubben Algorithm for modification of somatic cancer evolution
US20150056619A1 (en) 2012-04-05 2015-02-26 Bgi Diagnosis Co., Ltd. Method and system for determining copy number variation
CN104662171B (en) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 Individualized cancer vaccine and adoptive immunity cell therapy
EP2877594B1 (en) 2012-07-20 2019-12-04 Verinata Health, Inc. Detecting and classifying copy number variation in a fetal genome
WO2014138153A1 (en) 2013-03-06 2014-09-12 Life Technologies Corporation Systems and methods for determining copy number variation
AU2014251207B2 (en) * 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20150331992A1 (en) * 2014-05-15 2015-11-19 Ramot At Tel-Aviv University Ltd. Cancer prognosis and therapy based on syntheic lethality
MX2018004541A (en) * 2015-10-12 2019-04-15 Nantomics Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor.
WO2017106638A1 (en) * 2015-12-16 2017-06-22 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
WO2018005276A1 (en) * 2016-06-29 2018-01-04 The Johns Hopkins University Neoantigens as targets for immunotherapy

Also Published As

Publication number Publication date
AU2017299162A1 (en) 2019-02-07
PT3488443T (en) 2021-09-24
WO2018015433A2 (en) 2018-01-25
EP3967324A1 (en) 2022-03-16
WO2018015433A3 (en) 2018-03-01
MX2019000733A (en) 2019-05-02
DK3488443T3 (en) 2021-09-27
HUE056660T2 (en) 2022-03-28
JP2023009120A (en) 2023-01-19
KR102516166B1 (en) 2023-03-31
EP3488443A2 (en) 2019-05-29
IL264203A (en) 2019-02-28
IL264203B1 (en) 2024-04-01
KR20230019223A (en) 2023-02-07
BR112018077122A2 (en) 2019-04-30
SI3488443T1 (en) 2021-11-30
BR112018077122A8 (en) 2023-01-31
PL3488443T3 (en) 2021-12-20
EP3488443B8 (en) 2021-09-29
JP7171543B2 (en) 2022-11-15
SG10201912678QA (en) 2020-02-27
EP3488443B1 (en) 2021-08-18
LT3488443T (en) 2021-10-25
CA3031003A1 (en) 2018-01-25
JP2019524106A (en) 2019-09-05
HRP20211443T1 (en) 2021-12-24
ES2890424T3 (en) 2022-01-19
CN117757931A (en) 2024-03-26
RS62390B1 (en) 2021-10-29
US20190189241A1 (en) 2019-06-20
KR20190027832A (en) 2019-03-15
CY1124551T1 (en) 2022-07-22
CN109477149A (en) 2019-03-15

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201901364VA (en) Engineered target specific nucleases
SG11201811432WA (en) Rna for cancer therapy
SG11201907034PA (en) Methods of treating influenza
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201806261XA (en) Bcma antibodies and use of same to treat cancer and immunological disorders
SG11201808990QA (en) Compositions for topical application of compounds
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808108XA (en) Synthesis of indazoles
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201900132QA (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
SG11201804916PA (en) Three-dimensional polymer networks with channels situated therein
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201803642WA (en) Bacteria-based protein delivery
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201805755SA (en) Methods of administering hepcidin
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201908513RA (en) Peptides for treatment of diabetes